Management Change/Compensation (Form 8-K)

Resignation of Chief Executive Officer and Director

On January 30, 2026, Peter Liu, chief executive officer of DNA X, Inc. (formerly, Sonim Technologies, Inc.) a Delaware corporation (the "Company"), notified the Company's Board of Directors (the "Board") that he was resigning from the office of chief executive officer of the Company and as a director on the Board, effective as of the same date. Mr. Liu's resignation did not result from any disagreement with the Company.

As required by that certain employment agreement by and between Mr. Liu and the Company, dated as of December 8, 2023, as amended by that certain first amendment to employment agreement, dated April 2, 2025 (as amended, the "Liu Employment Agreement"), the separation and release agreement entered into by Mr. Liu and the Company (the "Liu Separation and Release Agreement") provided for Mr. Liu's general release of claims against the Company. Additionally, the Liu Separation and Release Agreement provided that the total cash severance payment owed to Mr. Liu pursuant to the Liu Employment Agreement ($855,000) is now payable in two tranches: the first payable three days after his execution of the Liu Separation and Release Agreement and the second payable on March 15, 2026. The Liu Employment Agreement previously provided that the cash severance payment would be paid in one lump sum payment not more than thirty days following separation.

Resignation of Chief Commercial Officer

On February 3, 2026, Charles Becher, chief commercial officer of the Company, notified the Board that he was resigning from the office of chief commercial officer of the Company, effective as of January 29, 2026.

As required by that certain employment agreement by and between Mr. Becher and the Company, dated as of August 23, 2022 (the "Becher Employment Agreement"), the separation and release agreement entered into by Mr. Becher and the Company (the "Becher Separation and Release Agreement" and, together with the Liu Separation and Release Agreement, the "Separation and Release Agreements") provided for Mr. Becher's general release of claims against the Company. Additionally, the Becher Separation and Release Agreement provides that the total cash severance payment owed to Mr. Becher pursuant to the Becher Employment Agreement ($250,000) is now payable in one lump sum payable within thirty days of January 29, 2026. The Becher Employment Agreement previously provided that the cash severance payment would be paid in equal monthly installments for a period of twelve months following separation.

The foregoing descriptions of the Separation and Release Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the Separation and Release Agreements, copies of which are filed as Exhibit 10.1 and Exhibit 10.2 hereto and incorporated by reference herein.

Director Appointment

On January 30, 2026, following Mr. Liu's resignation from the Board, the Board appointed Scott Walker to serve on the Board as a director. Mr. Walker will continue as a director until the next annual meeting of stockholders or until his successor has been elected and qualified, or, if sooner, until his earlier death, resignation or removal. Mr. Walker has not been appointed to any committee at this time. Mr. Walker has also entered into the Company's standard indemnification agreement for directors and officers.

Pursuant to that certain membership interest purchase agreement dated as of December 15, 2025 (the "Membership Interest Purchase Agreement"), by and between the Company and DNA Holdings Venture, Inc. ("DNA Holdings"), so long as DNA Holdings beneficially owns at least 5% of the Company, DNA Holdings will have the right to designate one director for election or appointment to the Board, subject to the oversight of the Company's nominating and governance committees. Accordingly, Mr. Walker's appointment is made pursuant to DNA Holdings' director designation right under the Membership Interest Purchase Agreement.

As previously reported on the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 18, 2025 , the Company and DNA Holdings entered into the Membership Interest Purchase Agreement, a securities purchase agreement (the "Securities Purchase Agreement") and a convertible promissory note in the original principal amount of $1,200,000.00, which bears interest at a rate of 10% per annum (the "Note" and, together with the Membership Interest Purchase Agreement and the Securities Purchase Agreement, the "DNA Agreements"). The description of the DNA Agreements is hereby incorporated by reference. Mr. Walker is a beneficial owner of DNA Holdings. The terms of the DNA Agreements were negotiated at arm's length prior to Mr. Walker's appointment to the Board. Mr. Walker may be deemed to have an indirect material interest in the DNA Agreements resulting from his beneficial ownership interest in DNA Holdings.

Mr. Walker, 64, is an investor and entrepreneur that has invested in or started over a dozen companies. Mr. Walker is co-founder of DNA Holdings, a digital asset investment and advisory firm. Since April 2024, Mr. Walker has served as the executive chairman of the board and chief executive officer of DNA Holdings. From 2004 to 2009, Mr. Walker served as chief executive officer of Extrinsic, Inc., a digital content and online marketing service. Mr. Walker has invested in several cryptocurrency-related projects, including the first-ever initial coin offering and later investing in Ethereum, Hedera, Casper, and dozens of other cryptocurrencies. Mr. Walker is currently a general partner at Coral Capital Holdings LLC, A195 Capital, Blockchain.Capital and a limited partner in other funds that have investments in Coinbase, Kraken, and Gemini. Mr. Walker was appointed to the Board based on his significant leadership experience and his extensive technical expertise in blockchain technology and cryptocurrencies.